Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy people aged 3 years and above;~* I (or/and his/her legal guardian/authorized representative) can comply with the requirements of the clinical trial protocol after informed consent and voluntary signed informed consent;~* No contraindications of quadrivalent influenza vaccine in the package insert and meet the vaccination requirements after medical history inquiry.~Exclusion Criteria:~* Allergy to any component of the quadrivalent influenza vaccine, including egg, excipients, formaldehyde, or Triton X-100;~* people with a history of anaphylaxis after vaccination (allergy to any previous vaccination);~* Acute disease, severe chronic disease, acute onset of chronic disease, cold and fever;~* Axillary body temperature ≥37.3℃ (\> 14 years old) and ≥37.5℃ (≤14 years old) before vaccination;~* Uncontrolled epilepsy;~* patients with progressive neurological disease or a history of Guillain-Barre syndrome;~* receiving immunoglobulin injection for less than one month;~* vaccination with live attenuated vaccine within 14 days before and other vaccines within 7 days before vaccination;

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Approval consistency study (Type: None): A total of 1050 recipients aged 18-59 years were enrolled in this study. Blood samples were collected before and 30 days after vaccination. Hemagglutination inhibition (HI) antibody to influenza virus was detected in the serum of all recipients to evaluate the inter-batch consistency of the vaccine.
- Safety and immunogenicity in a larger vaccination cohort aged 3 years and older (Type: None): 3850 recipients were enrolled in an open trial: safety observation after vaccination, follow-up for adverse events (AE) 30 minutes and 0-30 days after vaccination, and SAEs for 6 months after vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).